Most Read

Via its affiliates, the investor Sino Biopharmaceutical has invested around $500m in exchange for about 15% of the total equity interest of Sinovac LS. Earlier to the announcement

HMR59 is being developed to administer as a one-time, outpatient and intravitreal injection to protect vision in patients with geographic atrophy, a late-stage and severe form of age-related

PRA Health Sciences, a clinical research organisation (CRO) selected by Appili, will conduct the trial at 47 outpatient sites. Avigan, which is an antiviral in oral tablet form

The BNT162b2 mRNA vaccine is said to be the first in the world to secure EUA status to fight against Covid-19. The status was provided by the UK

Three drugmakers are part of the COVID R&D Alliance, which was established in March this year to boost the study candidates without regard to company affiliation. The alliance,

The mRNA-1273 is an mRNA vaccine against Covid-19 encoding for a prefusion stabilised form of the Spike (S) protein. It was co-developed by Moderna and investigators from NIAID’s

The company-sponsored study is being carried out in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and

CF, a rare and life-shortening genetic disease, that affects around 75,000 people across the globe. It is a progressive and multi-system disease that damages the lungs, liver, GI

1n 2019, Astellas and FibroGen have also received Japanese approval for roxadustat for the treatment of anaemia in adult patients with CKD and on dialysis. FibroGen now secures